On-Demand Webinar: Risk Sharing Agreements – Can “Innovative” Outcomes-Based Contracts Work?
There is a lot of buzz around a recent variation of Risk Sharing Agreements (RSAs) called “innovative” outcomes-based contracts, especially as more gene therapies receive approval. Several multimillion-dollar price-tag drugs have recently gained regulatory approval, with a record number of new cell and gene therapies (CGTs) up for regulatory decisions over the coming 2 years. […]